The US Food and Drug advisory panel has voted for the preliminary approval of Invokana (canagliflozin), Johnson and Johnson’s new type 2 diabetes drug, in a 10 to 5 vote. On the table during the discussion for this potentially innovative drug was the concern
Alexza Pharmaceuticals Inc. [NASDAQ: ALXA] expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of ADASUVE, being developed for schizophrenia or bipolar I disorder in adults.
Alexza Pharmaceuticals is an emer
Santarus, Inc. expects an FDA decision under the Prescription Drug User Fee Act (PDUFA) on the approval status of UCERIS, being developed for the treatment of induction of remission of mild to moderate active ulcerative colitis.
Santarus, Inc. is a sp